{"schema_version":"secwatch.filing_event.v1","accession":"0001628908-24-000051","form_type":"8-K","ticker":"EVH","cik":"0001628908","company_name":"Evolent Health, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.318427+00:00","generated_at":"2026-06-02T06:06:28.423371+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolent Health Q1 revenue $639.7M (+49.6% YoY); raises FY2024 revenue guide","bullets":["Revenue $639.7M, net loss $(25.2)M; Adjusted EBITDA $54.1M (8.5% margin).","Raises full-year 2024 revenue outlook; reiterates Adjusted EBITDA and exit-rate guidance.","Ends NIA transition services agreement; partners with Careology to accelerate patient navigation.","New Performance Suite with Molina for oncology/cardiology in SC and MS; MSK contract with east coast Medicaid plan.","Performance Suite average lives 7,050 (up from 3,242 YoY); specialty care revenue grew over 60%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628908-24-000051","json":"https://secwatch.observer/filing/0001628908-24-000051.json","markdown":"https://secwatch.observer/filing/0001628908-24-000051.md","text":"https://secwatch.observer/filing/0001628908-24-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000051/0001628908-24-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000051/evh-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:06:28.423371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61b35622a375ac78dea7bd94312601f6768aa423","claim":"Evolent Health, Inc. reported the quarter ended March 31, 2024 results: revenue $639.7 million, net income $(25.2) million. Guidance raised.","evidence_excerpt":"Evolent Announces First Quarter 2024 Results • Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. • Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890824000051/0001628908-24-000051-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$639.7 million"},{"label":"Net income","value":"$(25.2) million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}